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Background.Irondeﬁciencyanemiaimpactsoncognitivedevelopment.Theobjectiveofthisstudywastodeterminetheprevalence
of anemia and iron deﬁciency in children with Down syndrome and identify risk factors for anemia. Methods.W ec o n d u c t e da
prolective cross-sectional study of children attending a multidisciplinary Down syndrome medical center. One hundred and forty
nine children with Down syndrome aged 0–20 years were enrolled in the study. Information obtained included a medical history,
physical and developmental examination, nutritional assessment, and the results of blood tests. Results. Of the patients studied,
8.1% were found to have anemia. Among the 38 children who had iron studies, 50.0% had iron deﬁciency. In a multivariate
analysis, Arab ethnicity and low weight for age were signiﬁcantly associated with anemia. Gender, height, the presence of an eating
disorder, and congenital heart disease were not risk factors for anemia. Conclusions. Children with Down syndrome are at risk for
anemia and iron deﬁciency similar to the general population. Children with Down syndrome should be monitored for anemia and
iron deﬁciency so that prompt intervention can be initiated.
1.Introduction
Iron deﬁciency anemia (IDA) is prevalent and a major public
health care issue [1, 2]. IDA has been associated with motor
and cognitive developmental deﬁcits in children and may be
irreversible [3–7]. IDA may have an even greater impact on
select populations who are already at risk for intellectual and
developmental compromise.
Down syndrome (DS) is the most common human
aneuploidy with an approximate incidence of one in 800 live
births. Clinical manifestations of DS include cognitive im-
pairment, craniofacial dysmorphism, gastrointestinal tract
abnormalities, congenital heart defects, endocrine abnor-
malities, immunologic defects, and neurologic deﬁcits asso-
ciated with early onset dementia [8]. Regarding the hem-
atopoietic system, children with DS frequently show macro-
cytosis, abnormalities in platelet counts, and an increased
prevalence of leukemia [9–13]. Similar to the general pop-
ulation, individuals with DS may be at risk for IDA and its
consequent complications.
There are only a few studies regarding anemia in DS
patients. Until recently, those studies which have been pub-
lished often focused on a select population of children with
DS and may not be representative of the general DS pop-
ulation. For example, Awasthi et al. investigated the hema-
tological proﬁle of patients with DS who presented with ini-
tial manifestations of a hematological disorder to a genetics
clinic [14]. Of the 239 children with DS who were exam-
ined over a 10-year period, 6.2% were found to have a
hematological disorder. Of those 6.2%, 73.3% had acute
leukemia or transient myeloproliferative disorder (TMD).
Only 4 of the 239 children in the study (1.7%) were found
to have anemia. Henry et al. performed blood counts on
159 newborns (aged 0–7 days) with DS. These tests revealed
the prevalence of anemia to be no diﬀerent from the general
neonatal population. The authors suggested that anemia in
this age group may be more of a reﬂection of either maternal
iron stores or delivery-related newborn blood losses [15].
Dixon et al. performed blood counts and iron studies on
114 children with DS and found IDA in 3% and ID in 10%,2 International Journal of Pediatrics
comparable with their prevalence in the general pediatric
population [16].
The paucity of data on the prevalence of anemia in DS
patients of diﬀerent age groups and the deleterious con-
sequences associated with IDA lead us to investigate the
prevalence of anemia in this population and the speciﬁc risk
factors associated with IDA in children with DS.
2. Methods
2.1. Participants. During 2004–2007, 149 children and
young adults with DS were seen at the Center for Down Syn-
drome at the Hadassah Mount Scopus University Medical
Center, and these individuals were included in the study.
The Center for Down Syndrome serves the entire population
of Israel, and patients from the predominantly Arab neigh-
borhoods of East Jerusalem are actively recruited as part
of a cooperative (Israeli/Palestinian physicians) community-
based program to enhance the care of children with DS from
all ethnic backgrounds. As such, the center’s patient po-
ulation is representative of the general population of the
region. The study protocol was approved by the Hadassah-
Hebrew University Institutional Review Board (Helsinki
Committee).
The study was prolective, with the patient population
and data parameters deﬁned before data acquisition. The
patient population included children and young adults with
DS aged 0–20 years at their ﬁrst visit to the Center (before
any intervention). Patients were eligible for the study if they
hadacompletebloodcount(CBC)performedaspartoftheir
evaluation or had undergone blood testing within 3 months
of their visit (as part of the center’s protocol, we request that
parents or patients bring recent laboratory results). It should
be noted that all laboratory studies for outpatients in Israel
(there is universal health coverage for Israeli citizens) must
be approved by the patient’s health maintenance organiza-
tion (HMO), and HMOs have diﬀerent policies regarding
approvaloflaboratorytesting.Asubgroupof38childrenalso
had iron studies (iron, ferritin, and transferrin levels) either
performed at our center or at the child’s HMO. All partici-
pants arrived at the center for a general medical evaluation.
2.2. Measures. A complete medical history was taken and
patientsunderwent aphysicalexamination. Informationcol-
lected for the study included birth history, initial nutrition,
motor development, congenital malformations, and DS-
related complications (e.g., feeding disorders, oropharyn-
geal hypotonia, etc.). Anthropomorphic data was recorded
including BMI. Height and weight measurements were
analyzed in the context of growth charts developed for indi-
viduals with DS. The nutritional status of the patients was
assessed, and every patient was evaluated for the presence of
a feeding or nutritional disorder by the center’s dietitian and
speech therapist.
2.3. Statistical Methods. All hematinic study data was ana-
lyzed in terms of established age appropriate norms based
on the NHANES III [1]. Data was entered into a spreadsheet
Table 1: Demographic and clinical characteristics of patients.
Gender (M:F) 1.78
Age (mean, S.D., & range) 7.13 ±.53y
Age distribution (n,% ) 0 – 2 0y
0–2 41 (27.5)
2–6 42 (28.2)
6–10 15 (10.1)
≥10 51 (34.2)
Ethnicity
Jewish 127 (85.3)
Arabic 22 (14.7)
Heart defects 80/149 (53.7)
Feeding disorders 23/41 (56.1)
Motor delay 32/57 (56.1)
and imported to the SPSS statistical program (SPSS 15,
Chicago). Both nonparametric and parametric statistical
tools were used to analyze the data as appropriate. Associ-
ations between categorical variables were explored using the
χ2 test or Fisher’s exact test. Categorical variables found to
be associated with anemia in univariate analysis were further
analyzed in a logistic regression model.
3. Results
During the years 2004–2007, 303 children and young adults
were evaluated as ﬁrst-time patients at the Center for Down
Syndrome. Of these, 149 (49.0%) had the requisite data
to be included in the study. The demographic and clinical
data of the study group is shown in Table 1. There was
a greater proportion of males which is to be expected, as
there is male predominance among patients with DS. The
division between Jewish and Arab patients was close to the
population distribution in the region. More than half the
patients had heart defects, feeding disorders, and motor
delay. With regard to feeding disorders and delayed walking,
not all parents could recall this information or children had
not reached an age at which this could be determined.
The overall prevalence of anemia in our study group
was 8.1% (Table 2). The proportion of children with anemia
increased with age, with 13.7% of children over the age of
10 years having anemia. Likewise, the number of children
having blood hemoglobin that was lower than the published
NHANES III averages for diﬀerent age groups increased with
age.
Hematologic indices for the study group are shown in
Table 3. The majority of children did not have anemia or
m i c r o c y t o s i s .I r o ns t o r e sa sm e a s u r e db ys e r u mf e r r i t i n
indicated that nearly all children (26/27) tested had below
normallevelsforage.Incontrast,26childrenhadtheirserum
transferrin measured, and their levels were normal for their
age.
3.1. Risk Factors for Anemia. In univariate analysis, it was
found that age, ethnicity, weight, and motor developmentInternational Journal of Pediatrics 3
Table 2: Blood counts and iron studies (by age group).
Hemoglobin MCV Iron Ferritin Transferrin
0–2
Mean ± SD 13.38 ± 2.93 86.32 ± 8.76 36.13 ± 17.65 31.70 ± 21.77 254.80 ± 63.05
Range 8.80–22.50 73.10–110.0 5.41–57.20 5.30–70.30 167.00–365.99
N4 1 4 0 9 9 7
2–6
Mean ± SD 12.55 ± 1.13 84.44 ± 6.54 62.03 ± 32.68 19.47 ± 9.96 309.88 ± 36.80
Range 9.30–15.10 58.80–94.90 23.00–112.68 7.58–33.00 266.50–360.25
N4 2 4 1 1 0 7 6
6–10
Mean ± SD 13.30 ± 1 87.53 ± 4.73 60.40 ± 20.64 29.27 ± 18.24 270.81 ± 51.32
Range 11.0–14.80 75.80–94.10 28.70–89.00 4.28–46.10 207.00–377.72
N1 5 1 5 6 4 5
≥10
Mean ± SD 13.91 ± 1.4 90.17 ± 5.48 75.60 ± 63.66 53.09 ± 59.02 271.43 ± 34.54
Range 9.80–16.40 68.90–102.70 27.30–279.00 4.90–170.00 224.34–330.46
N5 1 4 9 1 3 7 8
Table 3: Anemia and low hemoglobin for age in age groups.
Age (years) Anemia N (%) Low hemoglobin for age∗
0–2 2/41 (4.9%) 13/41 (31.7%)
2–6 2/42 (4.8%) 12/42 (28.6%)
6–10 1/15 (6.7%) 6/15 (40%)
>10 7/51 (13.7%) 33/51 (64.7%)
Total 12/149 (8.1%) 64/149 (43%)
∗Lower than the published NHANES III age-related averages for hemo-
globin.
Table 4: Adjusted odds ratio (OR) for anemia in children with DS.
B S.E. Sig. Adjusted OR (C.I. 95%)
Ethnicity −1.483 0.709 0.036 0.227 (.057–.911)
Age 0.145 0.051 0.004 1.156 (1.047–1.277)
Weight −0.032 0.013 0.015 0.968 (0.944–0.994)
Constant −1.214 0.735 0.099 0.297
were related to an increased risk for anemia. Height, history
of feeding disorder, or congenital heart defects did not
increase the risk for anemia.
To determine the adjusted odds ratio for anemia, a lo-
gistic regression model was utilized (Table 4). The most
signiﬁcant risk factor for anemia was ethnicity. Patients of
Arabic ethnicity were found to have a nearly 5-fold increase
in anemia. Weight also had an impact on anemia, with the
rate of anemia decreasing by 0.03 with every increase by one
percentile in weight.
We also investigated variables associated with having
a below average hemoglobin for age. Interestingly, an as-
sociation between motor development and below average
hemoglobin concentration for age was found. When looking
attheageofindependentwalkingin53children,alowerthan
averagehemoglobin foragewasmoreprevalentamong those
who started walking after the age of 2 years (53.1% versus
24.0%, P<0.05).
4. Discussion
IDA is relatively common in the general population, and in
many countries and states, there are screening programs to
identify children with anemia. The reason for the heightened
concern regarding anemia is that IDA has been associated
with motor and cognitive developmental deﬁcits in children
[3–7]. In children with DS, whose intellectual capacity is
compromised to begin with, utmost attention should be
giventopreventinganemiaanditspotentiallydeleteriousde-
velopmental consequences.
In the present study, we show that the prevalence of
anemia in a general population of children with DS is 8.1%,
with the rate increasing with age. Factors associated with
anemia in this study included ethnicity and low weight.
There is a question of whether the relatively high rate
of anemia in our population is unique to DS or more
a reﬂection of the general population. Review of studies
done in the general Israeli population shows that IDA is an
endemic problem (similar to other countries in the Middle
East) [17–24], and it appears that the rates of anemia for
patients with DS in our clinic population were lower than
those of the general population. For example, Meyerovitch
et al. found anemia to be as high as 15.5% in 9–18-months
old infants [22]. Fraser et al. found a similar prevalence of
15% among Jewish children and approximately 25% among
Bedouin children [23]. Bilenko et al. reported a prevalence
as high as 47% [24]. It should be noted that the great
variabilitybetweenstudiesmayrepresentregionaldiﬀerences
and diﬀerent criteria for deﬁning anemia.
The higher prevalence of anemia among Arab children
with DS reﬂects a more wide-ranging trend among the gen-
eral population. Lavon et al. found a higher prevalence in4 International Journal of Pediatrics
Arabchildren:amongJewishchildren,therateofanemiawas
44.3% from birth to 6 months and increased to 60% from
the age of 6 months to one year. For similar age groups in the
Arabpopulation, the rateswere43.7% and 71% [25].Similar
diﬀerences between groups have been noted in other studies
[18, 23]. Meyerovitch et al. found that both Arab and ultra-
Orthodox Jews had increased rates of IDA [22]. It is possible
that ethnic and religious diﬀerences related to anemia are
secondarytosocioeconomicfactorswhichhaveanimpacton
adherence to Health Ministry recommendations regarding
iron supplementation [26].
The association that we found between low weight and
anemia supports the hypothesis that inadequate nutrition
may contribute to IDA and even explain some of the dif-
ferences found between diﬀerent ethnic populations. Cause
and eﬀect are diﬃcult to determine, as severe iron deﬁciency
alone may cause anorexia and poor weight gain. Other
factors, such as various chronic diseases which are more
prevalent in DS may also contribute to anemia. As part of
our initial evaluation of the participants, we ruled out celiac
disease,thusexcludingthisconditionasacontributingfactor
to IDA. However, it is possible that feeding disorders, which
are common among children with DS, may have caused
nutritional deﬁcits leading to anemia.
The prevalence of anemia is declining among the general
pediatric population in Israel [21, 22]. Public health initia-
tives have played a role in lowering the rate of anemia, and
children with DS have most likely beneﬁted from these inter-
ventions which include iron supplementation for all children
aged 4 months to one year, with continuation of supplemen-
tation if the CBC at one year of age indicates anemia.
There are several limitations to the present study. The
results of iron studies were available for only 38 of the 149
children we evaluated for anemia in this study. Thus, we
cannot truly characterize the anemia we found as IDA, or
identify risk factors associated with iron deﬁciency. We are
further limited in this by the presence of relatively high MCV
in this population, as discussed further below. Thalassemia
traitalsoremainsapossibleetiologyforanemiainthisethnic
population. However, as iron deﬁciency is the most common
cause of anemia in all age groups worldwide, and in the
absence of other proven causes of anemia in our study
population, iron deﬁciency remains the most likely cause of
the anemia found in this study.
The study population consisted of children who are in
the care of the Center for Children with Down Syndrome. It
is possible that they do not adequately represent the general
population of children with DS in Israel. Our population
mayoverrepresentfamilieswithhighcomplianceformedical
followup and treatment, and for this reason, they may have
a lower prevalence of anemia than other children with Down
syndrome. On the other hand, children with relatively mild
manifestations of DS may be underrepresented in our clinic
so that our study population is biased towards children with
moreseveremanifestationsofDSwhichmayimpacttherates
of anemia.
An interesting ﬁnding in our study was the tendency to
macrocytosis in all age groups. Macrocytosis is a common
ﬁnding in children with DS and has been widely reported
[16, 27–29]. Macrocytosis is not related to Vitamin B12 or
folic acid deﬁciencies, and most likely, there is a metabolic
or genetic reason for the macrocytosis. As a result, there
may be diﬃculty in completely characterizing IDA due to
macrocytosis. The clinical signiﬁcance of this point is that
the iron status of children with DS should be monitored by
both serial CBCs and iron studies.
5. Conclusions
The prevalence of IDA in children with DS does not greatly
diﬀer from the general population. Nevertheless, children
with DS and IDA might be more susceptible to the eﬀects of
anemia based on the fact that they already have DS-related
deﬁcits in motor and neurocognitive development. Since
IDA is an easily preventable and treatable problem when
diagnosed in a timely manner, it is important to monitor
children with DS by periodically performing a CBC and
measuring iron stores.
Authors’ Contribution
A. Tenenbaum and S. Malkiel contributed equally to this
work.
References
[1] A. C. Looker, P. R. Dallman, M. D. Carroll, E. W. Gunter, and
C. L. Johnson, “Prevalence of iron deﬁciency in the United
States,” Journal of the American Medical Association, vol. 277,
no. 12, pp. 973–976, 1997.
[2] J. C. McCann and B. N. Ames, “An overview of evidence for
a causal relation between iron deﬁciency during development
and deﬁcits in cognitive or behavioral function,” American
Journal of Clinical Nutrition, vol. 85, no. 4, pp. 931–945, 2007.
[3] D. Petranovic, T. Batinac, D. Petranovic, A. Ruzic, and T.
Ruzic, “Iron deﬁciency anaemia inﬂuences cognitive func-
tions,” Medical Hypotheses, vol. 70, no. 1, pp. 70–72, 2008.
[ 4 ]L .A g a o g l u ,O .T o r u n ,E .U n u v a r ,Y .S e ﬁ l ,a n dD .D e m i r ,
“Eﬀects of iron deﬁciency anemia on cognitive function in
children,” Arzneimittel-Forschung/Drug Research, vol. 57, no.
6, pp. 426–430, 2007.
[5] B. Lozoﬀ, “Iron deﬁciency and child development,” Food and
Nutrition Bulletin, vol. 28, no. 4, supplement, pp. S560–S571,
2007.
[6] J. C. McCann and B. N. Ames, “An overview of evidence for
a causal relation between iron deﬁciency during development
and deﬁcits in cognitive or behavioral function,” American
Journal of Clinical Nutrition, vol. 85, no. 4, pp. 931–945, 2007.
[7] T. Walter, “Eﬀect of iron-deﬁciency anemia on cognitive skills
and neuromaturation in infancy and childhood,” Food and
Nutrition Bulletin, vol. 24, no. 4, supplement, pp. S104–S110,
2003.
[8] N.J.RoizenandD.Patterson,“Down’ssyndrome,”TheLancet,
vol. 361, no. 9365, pp. 1281–1289, 2003.
[9] D. Webb, I. Roberts, and P. Vyas, “Haematology of Down syn-
drome,” Archives of Disease in Childhood,v o l .9 2 ,n o .6 ,p p .
F503–F507, 2007.
[10] M. C. Zwaan, D. Reinhardt, J. Hitzler, and P. Vyas, “Acute leu-
kemias in children with Down syndrome,” Pediatric Clinics of
North America, vol. 55, no. 1, pp. 53–70, 2008.International Journal of Pediatrics 5
[11] S. Malinge, S. Izraeli, and J. D. Crispino, “Insights into the
manifestations,outcomes,andmechanismsofleukemogenesis
in Down syndrome,” Blood, vol. 113, no. 12, pp. 2619–2628,
2009.
[12] N.J .RoizenandA.P .Amarose,“Hematologicabnormalitiesin
children with Down syndrome,” American Journal of Medical
Genetics, vol. 46, no. 5, pp. 510–512, 1993.
[13] B. Lange, “The management of neoplastic disorders of hae-
matopoiesis in children with Down’s syndrome,” British Jour-
nal of Haematology, vol. 110, no. 3, pp. 512–524, 2000.
[14] A. Awasthi, R. Das, N. Varma et al., “Hematological disorders
in Down syndrome: ten-year experience at a tertiary care cen-
tre in North India,” Pediatric Hematology and Oncology, vol.
22, no. 6, pp. 507–512, 2005.
[15] E. Henry, D. Walker, S. E. Wiedmeier, and R. D. Christensen,
“Hematological abnormalities during the ﬁrst week of life
among neonates with Down syndrome: data from a multihos-
pital healthcare system,” American Journal of Medical Genetics
A, vol. 143, no. 1, pp. 42–50, 2007.
[16] N. E. Dixon, B. G. Crissman, P. B. Smith, S. A. Zimmerman,
G.Worley,andP.S.Kishnani,“Prevalenceofirondeﬁciencyin
children with Down syndrome,” Journal of Pediatrics, vol. 157,
no. 6, pp. 967–971, 2010.
[17] E. Anour, M. Hasin, and Y. Yodfat, “Anemia in Jerusalem chil-
dren aged 3–6 years,” Harefuah, vol. 123, no. 10, pp. 373–436,
1992.
[18] J. Urkin, D. Adam, D. Weitzman, E. Gazala, S. Chamni, and
J. Kapelushnik, “Indices of iron deﬁciency and anaemia in
Bedouin and Jewish toddlers in southern Israel,” Acta Pae-
diatrica, vol. 96, no. 6, pp. 857–860, 2007.
[19] D. Merkel, M. Huerta, I. Grotto et al., “Prevalence of iron deﬁ-
ciency and anemia among strenuously trained adolescents,”
Journal of Adolescent Health, vol. 37, no. 3, pp. 220–223, 2005.
[20] G. Dubnov, A. J. Foldes, G. Mann, A. Magazanik, M. Siderer,
and N. Constantini, “High prevalence of iron deﬁciency and
anemia in female military recruits,” Military Medicine, vol.
171, no. 9, pp. 866–869, 2006.
[21] D. N. Kaluski, A. Leventhal, Y. Averbuch et al., “Five decades
of trends in anemia in Israeli infants: implications for food
fortiﬁcation policy,” European Journal of Clinical Nutrition,
vol. 55, no. 2, pp. 82–87, 2001.
[22] J. Meyerovitch, M. Sherf, F. Antebi et al., “The incidence
of anemia in an Israeli population: a population analysis
for anemia in 34512 Israeli infants aged 9 to 18 months,”
Pediatrics, vol. 118, no. 4, pp. e1055–e1060, 2006.
[ 2 3 ] D .F r a s e r ,D .S h a h a r ,I .S h a i ,H .V a r d i ,a n dN .B i l e n k o ,“ N e g e v
nutritional studies: nutritional deﬁciencies in young and eld-
erly populations,” Public Health Reviews, vol. 28, no. 1–4, pp.
31–46, 2000.
[24] N.Bilenko,M.Yehiel,Y.Inbar,andE.Gazala,“Theassociation
between anemia in infants, and maternal knowledge and ad-
herence to iron supplementation in Southern Israel,” Israel
Medical Association Journal, vol. 9, no. 7, pp. 521–524, 2007.
[25] B. Lavon, T. H. Tulchinsky, and M. Preger, “Iron deﬁciency
anemia among Jewish and Arab infants at 6 and 12 months
of age in Hadera, Israel,” Israel Journal of Medical Sciences, vol.
21, no. 2, pp. 107–112, 1985.
[26] S. Amsel, M. Boaz, A. Ballin, D. Filk, and N. Ore, “Low com-
pliance of iron supplementation in infancy and relation to
socioeconomic status in Israel,” Pediatrics, vol. 110, no. 2, pp.
410–411, 2002.
[27] O. David, G. C. Fiorucci, M. T. Tosi et al., “Hematological
studies in children with Down syndrome,” Pediatric Hematol-
ogy and Oncology, vol. 13, no. 3, pp. 271–275, 1996.
[28] T. J. Wachtel and S. M. Pueschel, “Macrocytosis in Down syn-
drome,” American Journal on Mental Retardation, vol. 95, no.
4, pp. 417–420, 1991.
[29] S. M. Kivivuori, J. Rajantie, and M. A. Siimes, “Peripheral
blood cell counts in infants with Down’s syndrome,” Clinical
Genetics, vol. 49, no. 1, pp. 15–19, 1996.